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Background: Bevacizumab (Avastin®) is as effective as ranibizumab (Lucentis®) in the treatment of neovascular
age-related macular degeneration (nAMD). However it has two important structural differences. First, it has two active
sites instead of one; second, it retains the Fc portion of the antibody which would be expected to confer a significantly
longer half-life. These agents have been associated with systemic complications including strokes, so it is desirable to
use the smallest effective dose. Furthermore, the standard dosing regimen requires monthly hospital visits, which
present a significant challenge both to the hospital services and to the patients (who are elderly).
Methods/Design: Patients ≥50 years who are eligible for anti-vascular endothelial growth factor (VEGF) treatment of
nAMD in the NHS, who are either newly referred for treatment or have reactivation of nAMD and who have not received
treatment to either eye for the previous six months.
We have designed a factorial multi-centre masked randomised controlled trial using bevacizumab as the intervention,
with patients randomised to one of four arms: to standard or low dose and to monthly or two-monthly patient review.
The aim is to recruit sufficient patients (around 1,000) to obtain 304 patients meeting the endpoint over a four-year
period. The primary endpoint is time to treatment failure to be analysed using Cox regression.
Discussion: This randomised control trial will show if half dose and two monthly as required is as effective as full dose
and monthly regimes. A two monthly as required regimen of Bevacizumab would significantly reduce both the cost
and the service delivery burden for the treatment of nAMD while a reduced dose would be expected to enhance the
safety profile of this treatment regime.
Trial registration: International Standard Randomised Controlled Trial Number: ISRCTN95654194, registered on 22
September 2009.
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The neovascular form of age-related macular degener-
ation (nAMD) is a major public health issue, with an es-
timated 26,000 people being eligible for treatment each
year in the United Kingdom [1]. Untreated, this disease
has a poor prognosis, with an average visual loss of one
to three lines at three months from diagnosis, and three
to four lines by one year, as measured by the logMAR
visual acuity chart [2]. The introduction of anti-vascular
endothelial growth factor (VEGF) agents have revolutio-
nised the treatment for this condition.
Introduction of the pan-VEGF inhibitors, bevacizumab
(Avastin®) and ranibizumab (Lucentis®) has transformed
the prognosis of nAMD. The first to be developed was
bevacizumab, which was an immunoglobulin G (IgG)
monoclonal antibody directed against VEGF. It was
shown to have powerful anti-angiogenic effects in an ex-
perimental tumour model [3] and was developed as an
anti-cancer drug. Ranibizumab was derived from the Fab
fragment of bevacizumab, which is a fragment of the
antibody that has the VEGF binding site.
Two landmark phase 3 trials, Minimally Classic/Occult
Trial of the Anti-VEGF Antibody Ranibizumab in the
Treatment of Neovascular Age-Related Macular Degeneration
(MARINA) and Anti-VEGF Antibody for the Treatment of
Predominantly Classic Choroidal Neovascularization in
Age-Related Macular Degeneration (ANCHOR), demon-
strated that ranibizumab gave large treatment benefits
[4,5]. Ranibizumab was administered by monthly intravit-
real injection into the vitreous cavity. At 12 and 24 months,
more than 90% of eyes treated with ranibizumab (0.5 mg)
remained within 15 letters (three lines) of the presenting
log MAR visual acuity chart compared to fewer than 64%
of eyes treated with photodynamic therapy (ANCHOR) [4],
or 62% of eyes treated with sham injections (MARINA) [5].
Of equal importance, eyes treated with ranibizumab
showed on average an increase in visual acuity (as mea-
sured by the logMAR visual acuity chart) of between five
and 10 (one to two lines), and about 35% had logMAR acu-
ity scores better than 70 letters (Snellen equivalent of six
out of 12) compared to eyes that had sham or other treat-
ments; this level of vision is compatible with visually de-
manding tasks such as fluent reading and driving.
Three large randomised control trials, Comparison of
Age-related Macular Degeneration Treatment Trial
(CATT) [6,7], alternative treatments to Inhibit VEGF in
Age-related choroidal Neovascularization IVAN [8,9] and
Groupe d'Etude Français Avastin versus Lucentis dans la
DMLA néovasculaire (GEFAL) [10], have demonstrated
non-inferiority of bevacizumab compared to ranibizumab
with respect to a non-inferiority margin of five letters.
There are two structural differences (see below) between
bevacizumab and ranibizumab, and these differences pro-
vide the rationale for the “Randomised controlled trial ofhigh and low dose Avastin® for Neovascular Macular
Degeneration in the East Midlands” (TANDEM) trial,
which uses a two-by-two factorial design to investigate
dosing and review and treatment frequency. This is ex-
plained in the next two sections.
Rationale for two-monthly arms and the issues of health
care delivery and ocular safety
The first factor compares monthly versus bimonthly re-
view. This factor is based on the observation that bevaci-
zumab retains the IgG Fc region. Molecules that possess
the Fc region have a long half-life in vivo [11-13]. The
existing data support the hypothesis that bevacizumab has
a longer-half life than ranibizumab. The half-life of ranibi-
zumab in the vitreous of rabbits is 2.9 days [14,15] com-
pared to a half-life of 4.3 days for bevacizumab [14]. In
humans, the reported half-life of bevacizumab is 10 days
[16] compared to the reported half-life for ranibizumab of
three days in primate eyes [16]. The ABC trial showed that
patients monitored and treated with bevacizumab on a
six-weekly basis had similar results to the ANCHOR and
MARINA trials [17]. In this context, it also is of interest
that aflibercept, which also has the structural motif of
retaining the IgG Fc portion, has been shown to be effect-
ive when given bimonthly [18,19].
Similar results to those seen in the ANCHOR and
MARINA trials can be achieved without continuous
dosing. The Prospective Optical Coherence Tomography
(OCT) Imaging of Patients with Neovascular Age-Related
Macular Degeneration (AMD) Treated with intraOcular
Ranibizumab (PrONTO) trial showed that a reduction in
treatment frequency can be achieved through rigorous tai-
loring of treatment to morphological parameters, with
comparable visual acuity outcomes [20,21].
Bimonthly dosing has not been investigated for ranibi-
zumab. The phase IIIb study of ranibizumab efficacy and
safety in choroidal neovascularization due to age-related
macular degeneration (PIERtrial showed that assessment
and re-treatment with ranibizumab once every three
months still gave good results, but not equal to those
achieved with monthly review [22]. The mean duration
of clinical action of bevacizumab has been reported to
be significantly longer than ranibizumab at 100 days
[23], and this suggests that monthly assessment and po-
tential treatment may be too frequent, and that a review
frequency of around every 56 days (eight weeks) should
be sufficient. Two-monthly dosing has the additional ad-
vantage of less frequent exposure to the risk of local
complications related to the injection process.
Rationale for low dose arms and the issue of systemic
safety
There is a second structural difference between bevaci-
zumab and ranibizumab. Bevacizumab has two binding
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ment, has only one; however, it should also be noted that
the target ligand is also bivalent. Binding studies of the
whole molecules of bevacizumab and ranibizumab are
broadly similar [24]. It is not clear how an ‘equivalent’
dose should be calculated given that the target ligand is
also bivalent.
The most commonly used dose of bevacizumab, 1.25 mg,
was calculated on the assumption that the dose should be
equimolar with respect to ranibizumab; this calculation
did not take into account the fact that bevacizumab has
two, rather than one, binding sites. Increasing the dose of
bevacizumab offers no increased clinical benefit; doses of
both 1.25 mg and 2.5 mg are equally effective in the treat-
ment of AMD [25,26]. Equally, increasing the dose of rani-
bizumab to 2.0 mg from the standard dose of 0.5 mg did
not result in a superior clinical result [27,28]. Moreover,
there is evidence that a lower dose may be just as effective.
In the context of diabetes, Avery et al. have shown that
proliferative disease will respond to an injected dose as
low of 0.00625 mg (6.25 μg) [29].
Concerns that these agents may cause both systemic
[7] and local complications, such as geographic atrophy
[30], make it desirable to use the smallest clinically ef-
fective dose. The combination of a half-dose adminis-
tered two-monthly would result in a potential four-fold
lowering of the total drug delivered during the mainten-
ance phase. The evidence described above suggests that
this is still a large enough dose to give a good clinical
response.Methods/Design
Study design
The trial is designed to test two hypotheses:
1. Low dose bevacizumab is not inferior to standard
dose bevacizumab with respect to maintenance of
visual acuity.
2. Following an initial three-month period of monthly
review, eyes reviewed every two months will not be
inferior to those reviewed monthly, with respect to
maintenance of visual acuity.
These hypotheses will be investigated using a two-by-
two factorial design. On entry into the trial, all patients
will be randomised between standard dose (1.25 mg) or
half dose (0.625 mg) of bevacizumab, and review every
four to six weeks or every eight to 10 weeks. All patients
will initially undergo three-monthly injections, and dur-
ing this phase the allocated frequency of subsequent re-
view will be masked from doctor and patient. This phase
is called the induction phase and is summarised in
Figure 1.On completion of the induction phase the review fre-
quency will be revealed and the patients will then enter
the maintenance phase. During this phase, re-treatment
is determined on the basis of optical coherence tomog-
raphy (OCT) findings, but treatment failure is assessed
on the basis of the logMAR visual acuity score. In both
arms, the treatment failure criteria are assessed every
eight to 10 weeks to avoid introducing bias by reviewing
one group more frequently.
The trial is designed to reflect current clinical practice.
There are no fixed criteria for patient discharge and each
participating unit can follow their own discharge policy.
Patients who are discharged from clinic are considered to
be ‘hibernating’, and if the disease reactivates then they will
be allowed to re-enter the trial, keeping their original ran-
domisation. These re-entering patients repeat the induc-
tion phase and a new baseline is established on re-entry.
Similarly, patients who develop bilateral disease re-
main in the trial. The fellow eye is treated according to
the same allocation as the first eye and undergoes the
initial three-month period of monthly review followed
by maintenance. The maintenance phase is summarised
in Figure 2.
Inclusion and exclusion criteria
This trial was designed to be as inclusive as possible,
thereby representing the patient population that presents
to the NHS requiring treatment for nAMD. It is a multi-
centre trial, with a number of participating hospitals lo-
cated in the East Midlands including Chesterfield, Derby,
Leicester, Lincoln, Mansfield and Nottingham.
The inclusion criteria reflect National Institute for
Health and Care Excellence (NICE) guidelines for treat-
ment of nAMD [31], and are:
1. Age ≥50 years,
2. Newly referred for treatment of nAMD or
reactivation of nAMD,
3. No treatment for nAMD to either eye for the
previous six months and
4. Eligible for anti-VEGF treatment of nAMD in the
NHS.
The exclusion criteria are those that apply to all pa-
tients being considered for treatment with an anti-VEGF
agent, namely:
1. Known hypersensitivity to recombinant human or
humanised antibodies,
2. Woman of child bearing potential and not willing to
use contraception,
3. Male with spouse of child bearing potential not
willing to use condoms or
4. Pregnant or breast feeding.
Figure 1 Flow diagram for the induction phase of the trial protocol. nAMD: neovascular Age Related Macular Degeneration. PIS: patient
information sheet. VA: visual acuity.
Foss et al. Trials  (2015) 16:85 Page 4 of 9The NICE guidelines state that patients with nAMD
are eligible for treatment with vision between six out of
12 and six out of 96 [31]. It is not standard practice in
the NHS for all patients to have a refraction before
checking their vision, however it is for entry into theTANDEM trial. Accordingly, patients approached about
the trial who meet the NICE guidelines on the basis of
vision testing with their current glasses (and would have
been treated in the normal NHS environment) remain
eligible for the trial even if their vision improves to
Figure 2 Flow diagram showing the maintenance phase of the trial protocol. VA: visual acuity.
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of the trial protocol. This decision was based on two
considerations. First, it was considered ethically difficult
to withdraw the offer of treatment once made, and sec-
ond, consideration was for the trial population to as ac-
curately reflect the patient population being treated
under the NHS as was reasonable.Trial participation
In view of the age and study population it will be expected
that the treating clinicians consider and determine
whether the potential trial patients have the capacity to
give fully informed consent to enter into the trial. If the
patient fulfils the eligibility criteria and agrees to enter the
trial, written informed consent is obtained. All patientswill receive trial participation information at least 24 hours
before being asked to give informed consent. Patients who
do not wish to consent to the trial will be treated in the
NHS according to standard care.Randomisation and masking
Randomisation is stratified by centre and blocked using
random permuted blocks of varying size. Allocation se-
quences are computer generated, and concealed from
staff recruiting participants to the trial using a secure
internet-based system created and maintained by Not-
tingham Clinical Trials Unit. Information to identify a
participant uniquely and to confirm eligibility must be
entered before the system assigns a study number and
treatment allocation.
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mologists, optometrists and nurses) are masked to the
bevacizumab dose. Patient allocation to monthly or two-
monthly review intervals is masked until three months
following allocation, but not thereafter.Source of trial drug
The bevacizumab syringes are manufactured, prepared
and shipped by The Royal Liverpool and Broadgreen
University Hospital via individually boxed syringes with a
tear-off sticker indicating the bevacizumab dose. Following
preparation of the prescription, the identifying label is re-
moved by the pharmacist, masking the syringe prior to
dispensing. The unique patient identifier is recorded on
the remaining masked label to ensure the correct patient
receives their allocated randomised treatment via their in-
travitreal injection.Data collection
Data collection comprises the following activities:
1. Baseline data collection (including general and
ophthalmic history, examination and baseline
morphology of nAMD lesion) at the initial visit;
2. Refraction at the initial visit and only at subsequent
visits, if required;
3. Early Treatment in Diabetic Retinopathy Treatment
Study (ETDRS) logMAR visual acuity score,
including checking visual acuity against criteria for
vision deterioration at the first three visits and at the
assessment reviews, but not at interim reviews
unless clinically indicated. Patients whose vision
dropped to the point that they meet the outcome
measure will have their visual acuity checked by an
independent observer;
4. Fundus fluorescein angiogram (FFA) and colour
photography is performed at the initial visit (images
sent for independent grading); then at each
subsequent visit if required (but not sent for
grading);
5. OCT and ocular examination is performed at the
initial visit and at assessment and interim reviews,
along with assessment for need for re-treatment (all
visits after visit C) and
6. Assessment of (serious) adverse events at all visits.
Separate screening and enrolment logs are maintained
for all patients screened and/or enrolled into the trial in
all participating centres. After a visit has taken place,
centre staff transfer data into a secure web-based data-
base within five working days. Baseline FFA and colour
images are submitted for grading.Image grading
A baseline colour fundus photograph and fluorescein
angiogram will be exported to the Network of Ophthalmic
Reading Centres (NetwORC) UK for image grading. The
angiographic grading will provide the area of active neo-
vascularisation (classic and any late leakage that occurs at
the site of irregular elevation of the retinal pigment epithe-
lium which will be considered as arising out of an occult
membrane located between the retinal pigment epithelium
(RPE) and the choroid). The area of blocked fluorescence
at the margins of the leakage which could represent occult
choroidal neovascularisation (CNV) will be measured sep-
arately. The area of blocked fluorescence will be matched
with the colour image to ensure that if this is due to blood,
this area will be outlined and reported separately to any
blocked fluorescence not due to blood. If areas of hyper
fluorescence are noted on the FFA adjacent to the optic
disk and associated with focal elevations of the RPE, the
grading form will include a comment indicating that there
is a high degree of suspicion that the lesion could represent
polypoidal choroidopathy. Similarly if reticular drusen,
choroidal thinning and intraretinal blood are observed and
the fluorescein leakage is dense and rapid, this will raise a
high index of suspicion of a retinal angiomatous prolifera-
tion (RAP) lesion.
Outcome
The primary outcome is time to treatment failure, de-
fined as loss of more than five letters (logMAR visual
acuity chart) from the baseline established as the average
of the visual acuities at the first three visits. The primary
analysis will be at the margins, unless there is evidence
of an interaction, in which case low dose plus bimonthly,
low dose plus monthly and standard dose plus bi-
monthly will each be compared with standard dose plus
monthly. There will be no correction for multiple com-
parisons [32].
Ethics approval
Ethical approval for this trial was granted by the Leicestershire,
Northamptonshire and Rutland Research Ethics Committee
(NRES reference 09/H0406/86).
Statistical considerations
Sample size
The target sample size is based on the primary hypoth-
eses, with the primary outcome analysed as a time-to-
event variable. When designing the study, we assumed
that there would be one study eye per participant, be-
cause this assumption is conservative and simplifies esti-
mation of sample size. Additionally, we assumed that the
annual risk of vision deterioration is 10% if allocated to
receive standard dose bevacizumab [9], and 10% if allo-
cated to monthly review intervals, and that there is no
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val. With a non-inferiority hazard ratio margin of 1.4 for
between-arm main effects, 90% power and one-sided 5%
alpha, a total of 304 events are required to be observed,
and the target sample size for recruitment was 2,000 par-
ticipants. In January 2014 after three years of recruitment,
we reviewed the assumptions underlying the original re-
cruitment target. Based on 437 randomised participants
and 374 person-years of observation, we revised the an-
nual event rate of the primary outcome from 10 to 20%,
and additionally accounted for annual censoring (death,
suspension of treatment following six months of stable
disease, withdrawal of consent for study participation or
no response to attempted contact) of 16%, which had not
been incorporated into the original calculation. The target
number of 304 events remains unchanged, but the target
number of randomised participants required to achieve
this has been revised to around 900 to 1,000.
Data analysis
Demographic and clinical characteristics at baseline of
participants in each of the four factorial cells will be de-
scribed using appropriate descriptive statistics. The main
approach to between-group comparisons will be to analyse
all participants as randomised regardless of adherence
with allocation. In addition for the primary outcome, a per
protocol analysis will be conducted that excludes partici-
pants with protocol violations (specifically, failure to col-
lect outcome data or patients who received treatment in
addition to the trial intervention, such as ranibizumab).
All regression models will include centre as a fixed effect,
since this was used in stratifying randomisation.
Since participants may have one or both eyes included
in the study, analysis of the primary outcome will be car-
ried out using shared-frailty Cox regression models. Effi-
ciency of the two-by-two factorial design is realised
when all participants are included in estimating the ef-
fects of both factorial elements. Therefore the analysis
will first explore whether the effect of low versus stand-
ard dose bevacizumab, and two-monthly versus monthly
review interval, differs according to the presence or ab-
sence of the other. If there is no evidence of an inter-
action, main effects will be estimated by including a
separate term for each in the model. If there is evidence
of an interaction, then the effects of reduced dose alone
and increased interval alone will be estimated using the
factorial cells, with accordingly reduced sample sizes for
these comparisons. Secondary analyses of the primary
outcome will include additional adjustment for any vari-
ables exhibiting marked imbalance at baseline, and in-
vestigation of subgroup effects according to: baseline
visual acuity in study eye ≤44 versus >44; 2) baseline
CNV size ≤4 versus >4 and nAMD lesion composition.
These analyses will be conducted by fitting interactionterms to the regression models. It is recognised that the
study is not powered to detect differential treatment ef-
fects among subgroups, and these analyses will be
viewed as exploratory.
Secondary outcomes will be analysed using a similar
approach as for the primary analysis, with regression
model appropriate for type of outcome. All between-
group comparisons will be described using appropriate
estimates of effects (that is, hazard ratio, odds ratio or
difference in means, depending on outcome type) and
95% confidence intervals.Discussion
The use of the anti-VEGF agents has transformed the
prognosis of patients with nAMD. However there are
two major barriers to the delivery of health care to this
group of patients. The first is the cost and the second is
the requirement to be seen monthly. The TANDEM trial
is designed to investigate both of these barriers.
The CATT, IVAN and GEFAL trials have shown that
bevacizumab is not inferior to ranibizumab in the treat-
ment of nAMD [7,9,10], and there is a strong health
economic incentive for its use, notwithstanding the
current regulatory situation. However, there are very
limited trial data guiding the most beneficial way to use
bevacizumab.
The optimum dose for bevacizumab is not known and
there is considerable evidence suggesting that a lower
dose may be equally beneficial. This is important while
concerns over the safety of the pan-VEGF inhibitors re-
main, as one would expect the lower dose to carry a bet-
ter safety profile. However, adverse event rates are low
and this study is not powered to detect any difference in
adverse and serious adverse events.
The second issue is that of frequency. Ophthalmic de-
partments are struggling to meet the one-monthly re-
view schedule that the use of ranibizumab requires.
There is reason to believe that it would be effective
when given on a two-monthly regimen, which in turn
would halve the required number of out-patient assess-
ment visits.Trial status
Recruitment to the TANDEM trial is ongoing. First pa-
tient was randomised in Novemeber 2010 and recruit-
ment is expected to end at the end of 2016.Abbreviations
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